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Abstract: Elderly individuals are at increased risk of coronary heart disease (CHD) and account 
for a majority of CHD deaths. Several clinical trials have assessed the beneﬁ  cial effects of 
statins in individuals with, or at risk of developing, CHD. These trials provide evidence that 
statins reduce risk and improve clinical outcomes even in older patients; however, statin therapy 
remains under-utilized among the aged. Atorvastatin has been widely investigated among the 
older subjects and has the greatest magnitude of favorable effects on clinical outcomes of CHD. 
The pharmacokinetic properties of atorvastatin allow it to be used every other day, a factor which 
may decrease adverse events and be especially important in the elderly. The purpose of this 
article is to review the evidence available from randomized clinical trials regarding the safety 
and efﬁ  cacy of atorvastatin in primary and secondary prevention of CHD and stroke in older 
patients and to discuss issues such as drug interactions, patient compliance and cost-effectiveness, 
which affect prescription of lipid-lowering therapy among older patients.
Keywords: atorvastatin, statins, HMG-CoA reductase inhibitors, coronary heart disease, 
elderly patients
Introduction
The proportion of older persons ( 60) is projected to more than double worldwide over 
the next half century. The older population is expanding faster than the total population 
throughout the world and this difference in growth rates is increasing (UN 2001). Data 
from the Framingham Heart Study show that the cumulative risk of CHD rises steeply 
after age 60 years until age 90 years, at which time cumulative risk seems to plateau 
(Lloyd-Jones et al 1999). Therefore, such a shift in the demographic proﬁ  le will lead to 
increased incidence of cardiovascular disease, including CHD, heart failure, and stroke 
(Bonow et al 2002). Heart disease (30.4%) and stroke (7.4%) were the ﬁ  rst and third 
leading causes of mortality and morbidity in 2004 among adults aged 65 years and 
older in the US (Miniño et al 2007). Incidence of new CHD events is greatest among 
persons  65 years of age and this group accounts for 83% of CHD deaths (Rosamond 
et al 2007). New modalities of treatment have managed to reduce death rates from 
acute coronary events. This has resulted in people with CHD living longer leading to 
increased prevalence among the elderly. Besides advancing age, other cardiovascular 
risk factors are also more prevalent among the elderly population. Dietary indiscretion 
along with sedentary lifestyle has led to increased prevalence of the metabolic syndrome 
among older adults (Ford et al 2004). Insulin resistance, abdominal obesity and lipid 
abnormalities accompany this syndrome, which are known CHD risk factors.
Elevated total serum cholesterol has been associated with risk of CHD in older men 
and women in various large-scale studies (Castelli et al 1989; Benfante et al 1990; 
Rubin et al 1990; Frost et al 1996; Houterman et al 1999). The Framingham data and 
the Systolic Hypertension in the Elderly Program (SHEP) have demonstrated that high 
levels of low-density lipoprotein cholesterol (LDL-C) and low levels of high-density Clinical Interventions in Aging 2008:3(2) 300
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lipoprotein cholesterol (HDL-C) were associated with 
CHD risk in older patients (Castelli et al 1989; Frost et al 
1996). However, others have pointed out that the associa-
tion between total serum cholesterol and risk of coronary 
artery disease diminishes with increasing age (Shipley et al 
1991; Kronmal et al 1993; Assmann et al 1998). Thus, the 
rationale for treatment of elevated cholesterol levels in the 
elderly is less clear.
Therapy with statins has been shown to effectively 
reduce the incidence of major coronary events in pri-
mary prevention and particularly in secondary preven-
tion settings, in several prospective randomized clinical 
research studies (Pedersen et al 1994; Shepherd et al 1995; 
Sacks et al 1996; Downs et al 1998; LIPID Study Group 
1998; HPSCG 2002; Shepherd et al 2002; Sever et al 2003; 
Cannon et al 2004; Colhoun et al 2004; LaRosa et al 2005; 
Deedwania et al 2007). Unfortunately, the early statin trials 
have suffered from signiﬁ  cant age and gender bias, as most 
of them recruited relatively small numbers of women and 
elderly subjects, resulting in inadequate representation of that 
group of patients (Bandyopadhyay et al 2001). In the recent 
secondary prevention guidelines from the American Heart 
Association (AHA) and the American College of Cardiology 
(ACC), the writing group has acknowledged this fact and has 
urged physician and patient participation in trials that will 
provide additional evidence for lipid-lowering therapy in the 
elderly (Smith et al 2006). Physicians have been reluctant to 
prescribe these drugs in older adults due to a perceived lack of 
indication (Cournot et al 2006). There has been a belief that 
cholesterol lowering therapy must be continued for prolonged 
periods before any beneﬁ  cial effect can be observed on the 
underlying atherosclerosis. There are also concerns regard-
ing increased risk of adverse events (Cournot et al 2006) 
and drug interactions, as well as the effect of statins on the 
various comorbidities in this age group. Patient non-compli-
ance and adherence to long term statin treatment are other 
important considerations (Benner et al 2002; Jackevicius 
et al 2002; Benner et al 2005). Doubts have been raised about 
the cost-effectiveness of statin use for primary prevention 
in the elderly. Studies suggest that statins remain largely 
underutilized in elderly patients even in secondary prevention 
settings, where they have proven beneﬁ  ts (Ghosh et al 2002; 
Rasmussen et al 2005). Data from the National Registry of 
Myocardial Infarction 3 (Fonarow et al 2001) and the Global 
Registry of Acute Coronary Events (GRACE) (Avezum et al 
2005) further support this assertion.
In this review, we look at the elderly subgroup from 
the major primary and secondary prevention statin trials, 
with a special focus on atorvastatin. We discuss the basic 
mechanisms of action of atorvastatin as well as issues of 
safety, tolerability, drug interactions and patient compliance. 
We also make recommendations regarding management 
strategies in older CHD patients, and place of atorvastatin 
in therapy.
Pharmacology of statins
and pleiotropic effects
Atorvastatin is a potent intrinsically active inhibitor of 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase which is the rate-limiting enzyme in de novo 
cholesterol synthesis. This enzyme inhibition lasts for 
20–30 hours, given that its elimination half-life (14 hours) 
is longer than all statins except rosuvastatin (19 hours), and 
its active metabolites persist for even longer periods of time 
(Lea et al 1997). HMG-CoA reductase inhibitors reduce the 
production of mevalonic acid from HMG-CoA, resulting 
in a reduction in hepatic cholesterol synthesis. This in turn 
results in a compensatory increase in the expression of high-
afﬁ  nity LDL receptors on hepatocyte membranes leading to 
an increased catabolism of LDL and its precursors, resulting 
in decreased LDL production (Brown et al 1986). Reduc-
tions in the hepatic pool of cholesterol have been associated 
with a decrease in the rate of production of very-low-density 
lipoprotein (VLDL) by the liver (Thompson et al 1996). 
Atorvastatin decreases hepatic apo B secretion, which lowers 
VLDL production (Conde et al 1996).
In addition to decreasing cholesterol levels, statins affect 
atherosclerosis by several other effects such as plaque sta-
bilization, reduced inﬂ  ammation, reversal of endothelial 
dysfunction, and decreased thrombogenicity. These effects 
seem unrelated or only partially related to the lipid lower-
ing effect.
Using coronary intravascular ultrasound, atorvastatin 
has been shown to retard the progression of plaque volume 
and increase plaque hyperechogenicity (Schartl et al 2001; 
Nissen et al 2004). Increased hyperechogenicity correlates 
with change in plaque composition from an unstable lipid-
rich lesion to a plaque with a larger fraction of calcium and 
collagen. Such a change increases stability and decreases 
the tendency for plaque disruption leading to an acute CHD 
event. The Reversal of Atherosclerosis With Aggressive 
Lipid Lowering (REVERSAL) trial (Nissen et al 2004) 
showed that the rate of progression was slower with atorv-
astatin 80 mg/day compared to pravastatin 40 mg/day, at any 
level of LDL-C reduction suggesting the role of pleiotropic 
effects in the improved outcome.Clinical Interventions in Aging 2008:3(2) 301
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Atorvastatin therapy reduces the serum C reactive 
protein (CRP) concentration signiﬁ  cantly, which suggests 
an anti-inﬂ  ammatory action (Jialal et al 2001). Atorvastatin 
80 mg/day reduced CRP levels to a greater extent than 
either simvastatin 40 mg/day or pravastatin 40 mg/day in 
the Atorvastatin versus Simvastatin on Atherosclerosis 
Progression (ASAP) (van Wissen et al 2002) and REVER-
SAL (Nissen et al 2004) trials, respectively. The decrease in 
CRP was signiﬁ  cantly correlated with reduction of intima 
media thickness of carotid artery segments in the ASAP 
study. In the Trial of Atorvastatin in Rheumatoid Arthritis 
(TARA) study, atorvastatin caused a clinically apparent 
reduction in inﬂ  ammation in rheumatoid arthritis patients, 
along with reduced CRP and erythrocyte sedimentation rate 
(McCarey et al 2004). Reduction in expression of endothe-
lial adhesion molecules (ICAM-1, VCAM-1, E-selectin and 
P-selectin) also contributes to the anti-inﬂ  ammatory effect 
(Seljeﬂ  ot et al 2002).
Atorvastatin improves the endothelial dysfunction 
associated with atherosclerosis and this effect is seen within 
24 hours, before its effects on CRP and cholesterol become 
evident (Marchesi et al 2000; Laufs et al 2001). Statins prevent 
downregulation of endothelial nitric oxide synthase and may 
directly upregulate its activity, leading to increased bioavail-
ability of nitric oxide. They also have an action on the endo-
thelial progenitor cells (Martinez-Gonzalez et al 2007).
Atorvastatin decreases thrombogenicity and improves 
hemorrheological parameters within a few months of 
treatment. Decrease in whole blood viscosity and collagen-
induced platelet aggregation, improvement in red blood 
cell deformability and reduction in Von Willebrand factor 
(vWf) concentration are some of the possible mechanisms 
(Szapary et al 2004).
Secondary prevention trials
with atorvastatin
Beneﬁ  cial effects of atorvastatin have been widely investi-
gated both in patients with stable CHD and in patients with 
recent acute coronary events. Table 1 summarizes the effects 
of atorvastatin on major clinical endpoints in various second-
ary prevention trials.
Stable CHD with clinical endpoints
The Study Assessing Goals in the Elderly (SAGE) trial 
was the ﬁ  rst trial to speciﬁ  cally investigate intensive statin 
therapy in elderly CHD patients (Deedwania et al 2007). 
Eight hundred ninety three patients aged 65–85 years with 
stable CHD, baseline LDL-C levels between 100 mg/dL 
and 250 mg/dL who had at least one episode of ischemia on 
baseline screening with 48-hour ambulatory ECG monitor-
ing were randomly assigned to treatment with atorvastatin 
80 mg/day or pravastatin 40 mg/day and followed up 
for 12 months. Compared with pravastatin, atorvastatin-
treated patients experienced signiﬁ  cantly greater decreases 
in LDL-C (55% vs 32% at 12 months), total cholesterol, 
triglycerides, and apolipoprotein B at months 3 and 12 (all 
p   0.001). The total duration of ambulatory myocardial 
ischemia (the primary efﬁ  cacy parameter) was equally and 
signiﬁ  cantly reduced from baseline in both groups (both 
p   0.001) as early as 3 months with improvement persisting 
at one year. There was a 77% reduction in all-cause mor-
tality (1.3 vs 4%, hazard ratio [HR] 0.33, 95% conﬁ  dence 
interval [CI] 0.13–0.83, p = 0.014) and a trend toward fewer 
major acute cardiovascular events (8.1 vs 11.2%, HR 0.71, 
95% CI 0.46–1.09, p = 0.114) with atorvastatin relative to 
pravastatin at the end of month 12. Thus, older men and 
women with CHD were shown to beneﬁ  t with intensive 
atorvastatin therapy.
In the Treating to New Targets (TNT) study, 10,001 
patients (3809 patients  65 years) with CHD and 
LDL-C  130 mg/dL were randomized to receive ator-
vastatin 10 mg/day or 80 mg/day and followed up for a 
median of 4.9 years (LaRosa et al 2005). The high-dose 
atorvastatin group showed a lower mean serum LDL-C 
concentration (77 vs 101 mg/dL) along with a 22% relative 
reduction in the rate of the composite primary end point of 
death from CHD, nonfatal non-procedure-related myocar-
dial infarction (MI), resuscitation after cardiac arrest, or 
fatal or nonfatal stroke (8.7% vs 10.9%, HR 0.78, 95% CI 
0.69–0.89, p = 0.001). Reductions were also seen in non-fatal 
MI (HR 0.78, 95% CI 0.66–0.93, p = 0.004) and fatal or 
nonfatal stroke (HR 0.75, CI 0.59–0.96, p = 0.02). A second-
ary analysis of the TNT study in patients  65 years of age 
demonstrated a 19% reduction in relative risk (RR) for major 
cardiovascular events in favor of the high-dose atorvastatin 
group (HR 0.81, 95% CI 0.67–0.98, p = 0.032) (Wenger 
et al 2007). Absolute risk reduction was similar in older and 
younger patients with intensive atorvastatin therapy (2.3% 
in both groups). No statistically signiﬁ  cant heterogeneity of 
treatment effect for age was seen for the primary outcome (or 
its individual components) or secondary outcomes. Elderly 
subjects in the atorvastatin 80 mg/day group had lower rates 
of CHD death, nonfatal non-procedure-related MI, and fatal 
or nonfatal stroke, although the difference did not reach statis-
tical signiﬁ  cance. This trial also suggested that high-risk older 
patients with established CHD could beneﬁ  t from intensive Clinical Interventions in Aging 2008:3(2) 302
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atorvastatin therapy and lowering LDL-C levels to less than 
100 mg/dL could provide incremental clinical beneﬁ  t.
The Incremental Decrease in End points through Aggres-
sive Lipid lowering (IDEAL) trial recruited 8888 patients 
aged  80 years with a history of acute MI, and randomly 
assigned them to receive high-dose atorvastatin (80 mg/day) 
and usual-dose simvastatin (40 mg/day) (Pedersen et al 
2005). Compared with simvastatin, atorvastatin-treated 
patients experienced signiﬁ  cantly lower mean levels of LDL-
C (81 vs 104 mg/dL), total cholesterol, and triglycerides (all 
p   0.001) after a median follow-up of 4.8 years. The primary 
clinical outcome was time to ﬁ  rst occurrence of a major 
coronary event deﬁ  ned as coronary death, hospitalization 
for nonfatal acute MI, or cardiac arrest with resuscitation. 
The primary outcome was nonsigniﬁ  cantly reduced with 
atorvastatin (9.3 vs 10.4 %, HR 0.89, 95% CI 0.78–1.01). 
There were signiﬁ  cant reductions in rates of nonfatal acute 
MI (HR 0.83, 95% CI 0.71–0.98, p = 0.02) and major cardio-
vascular events (HR 0.87, 95% CI 0.77–0.98, p = 0.02). No 
separate data were published regarding elderly participants 
in the study. However, a preliminary analysis by the authors 
did not reveal any statistically signiﬁ  cant treatment group 
interactions by age.
Stable CHD with atheroma 
volume as endpoint
The Reversal of Atherosclerosis with Aggressive Lipid 
Lowering (REVERSAL) trial randomized 654 patients 
to receive pravastatin 40 mg/d or atorvastatin 80 mg/day 
(Nissen et al 2004). Five hundred two had evaluable intra-
vascular ultrasound examinations at baseline and after 18 
months of treatment. The atorvastatin group experienced 
greater reductions in levels of LDL-C (46 vs 25%), total 
cholesterol, triglycerides and apo B (all p   0.001). CRP 
was reduced by 5.2% with pravastatin and 36.4% with 
atorvastatin (p   0.001). A signiﬁ  cant percentage change in 
total atheroma volume (primary end point) occurred in the 
pravastatin group (+2.7%, 95% CI 0.2%–4.7%, p = 0.001), 
indicating progression of atherosclerosis compared to base-
line. No progression was noted with atorvastatin and percent-
age change in total atheroma volume was negative (−0.4%, 
CI −2.4% to 1.5%, p = 0.98). Thus, aggressive lipid-lowering 
with atorvastatin signiﬁ  cantly reduced disease progression 
compared to pravastatin (−0.4% vs 2.7%, p = 0.02). Differ-
ences were seen between the treatment groups for secondary 
endpoints such as total atheroma volume (p = 0.02), change 
in percentage atheroma volume (p   0.001), and change 
in atheroma volume in the most severely diseased 10-mm 
vessel subsegment (p   0.01), all favoring the atorvastatin 
group. For 231 patients aged equal to or greater than the 
median age (56 years), change in atheroma volume was 4.8% 
with pravastatin (p   0.001) and −1.5% with atorvastatin 
(p = 0.67). The therapeutic regimens were signiﬁ  cantly dif-
ferent in this older group (p = 0.01), but similar in younger 
patients (p = 0.75). Linear regression analysis indicated that, 
for any given level of LDL-C reduction, the progression rate 
was lower with atorvastatin compared with pravastatin for 
all patients. A subsequent analysis concluded that in addi-
tion to lipid lowering, the greater effect of atorvastatin on 
CRP might be responsible for slower disease progression 
(Nissen et al 2005).
Acute coronary syndrome (ACS) 
with clinical endpoints
The Pravastatin or Atorvastatin Evaluation and Infec-
tion Therapy Thrombolysis in Myocardial Infarction 
(PROVE IT-TIMI) 22 trial evaluated the effects of standard 
(LDL-C   100 mg/dL) versus intensive (LDL-C   70 mg/dL) 
lipid lowering using pravastatin 40 mg/d and atorvastatin 80 
mg/d, respectively, in 4162 patients (730 patients  70 years) 
hospitalized with ACS within the preceding 10 days (Cannon 
et al 2004). Patients were required to have a baseline total 
cholesterol concentration of  240 mg/dL if not on prior 
therapy or  200 mg/dL if on lipid-lowering therapy at the 
time of the ACS. After a mean follow-up of 2 years, median 
LDL-C levels decreased more with atorvastatin compared 
with pravastatin in statin-naïve patients (51% vs 22 %) as 
well as among patients previously on statin therapy (32% 
vs 0%). The primary end point was a composite of death 
from any cause, MI, documented unstable angina requiring 
rehospitalization, revascularization and stroke. The primary 
end point was reduced by 16% with atorvastatin relative to 
pravastatin (22.4% vs 26.3%, HR 0.84, 95% CI 0.74–0.95, 
p = 0.005). The beneﬁ  t of atorvastatin became apparent as 
early as 30 days after randomization and was consistent over 
time. Similar beneﬁ  t or a trend toward beneﬁ  t was seen in all 
the individual components of the primary end point with the 
exception of stroke. Post-hoc analysis of patients  70 years 
of age revealed that a greater proportion of patients achieved 
the LDL-C goals at 30 days in the atorvastatin 80 mg/day 
group versus those allocated pravastatin 40 mg/d (74.6% 
vs 27.7%, p   0.001) (Ray et al 2006). Achievement of 
the LDL-C goal of  70 mg/dL was associated with a 40% 
lower risk of death, MI, or unstable angina compared to older 
patients who did not reach goal (13.5 vs 21.5% absolute 
rates, respectively; HR 0.60, 95% CI 0.41– −0.87, p = 0.008). Clinical Interventions in Aging 2008:3(2) 304
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To prevent 1 cardiovascular event, only 13 elderly subjects 
needed to achieve the LDL-C goal compared to 43 younger 
subjects. Thus, nearly 4 times as many acute events could be 
potentially prevented among the elderly by lowering LDL-C 
to  70 mg/dL (80 vs 23 events prevented for every 1000 
patients at goal over 2 years).
The Myocardial Ischemia Reduction with Aggressive 
Cholesterol Lowering (MIRACL) study was also done in 
the post-ACS setting. 3086 adults (1672 patients  65 years) 
with unstable angina or non-Q-wave MI were randomized 
to 16 weeks of atorvastatin 80 mg/day or placebo 24–96 
hours after hospital admission (Schwartz et al 2001). The 
primary end point (nonfatal infarction, cardiac arrest with 
resuscitation, or recurrent symptomatic ischemia requiring 
hospitalization) was signiﬁ  cantly reduced with atorvastatin 
(14.8 vs 17.4%, RR 0.84, 95% CI 0.70–1.00, p = 0.048) pri-
marily due to a 26% reduction in recurrent ischemic events 
(RR 0.74, 95% CI 0.57–0.95, p = 0.02). A post hoc analysis 
of older patients in the study was done using treatment-by-
age heterogeneity tests (Olsson et al 2007). Similar relative 
reductions in the primary end point were seen in younger and 
older patients with atorvastatin (22% vs 14%, p = 0.62). The 
Number Needed to Treat (NNT) was 34 among the elderly, 
compared to 40 among younger subjects. There was no 
difference in treatment effect between these two groups for 
any of the individual components of the primary end point 
or secondary end points. In patients  80 years of age, there 
was a 34% reduction in relative risk of the primary end point 
with atorvastatin compared with placebo (HR 0.66, 95% CI 
0.57–1.00, p = 0.05).
Together, these studies demonstrated that high risk elderly 
individuals with stable coronary artery disease (SAGE, TNT, 
IDEAL) as well as those with recent acute events (PROVE 
IT, MIRACL) beneﬁ  t from lipid lowering with statins. The 
improvement in clinical outcomes was at least similar to, 
if not greater than, that seen with middle-aged individuals. 
They also suggested that a lower LDL-C goal was associated 
with a better outcome. The REVERSAL trial proved that 
even within a short duration of 18 months, progression of 
atherosclerosis could be measurably reduced with intensive 
atorvastatin therapy. Use of atorvastatin is, therefore, reason-
able and justiﬁ  ed for the purpose of secondary prevention 
in elderly patients.
Primary prevention trials 
with atorvastatin
Compared with secondary prevention studies, the data 
regarding the use of statin therapy for the primary prevention 
of CHD in high-risk elderly patients are somewhat limited. 
Efﬁ  cacy data from primary prevention trials using atorvas-
tatin are presented in Table 2.
The Collaborative Atorvastatin Diabetes Study (CARDS) 
was a randomized placebo-controlled trial investigating 
atorvastatin 10 mg/d for primary prevention of CHD in 2838 
patients (1129 patients  65 years) with type 2 diabetes with 
LDL-C  160 mg/dL, a fasting triglyceride  600 mg/dL and 
at least one of the following: retinopathy, albuminuria, cur-
rent smoking, or hypertension (Colhoun et al 2004). Median 
duration of follow-up was 3.9 years as the trial was termi-
nated 2 years earlier than planned because a prespeciﬁ  ed early 
stopping rule for efﬁ  cacy had been met. A 37% reduction 
in incidence of major cardiovascular events was seen with 
atorvastatin (HR 0.63, 95% CI 0.48–0.83, p = 0.001). When 
assessed separately, acute CHD events were reduced by 36% 
(HR 0.64, 95% CI 0.45–0.91), coronary revascularizations by 
31% (HR 0.69, 95% CI 0.41–1.16) and rate of stroke by 48% 
(HR 0.52, 95% CI 0.31–0.89) (all p = 0.001). A subsequent 
analysis comparing patients aged 65–75 years with younger 
patients revealed that atorvastatin treatment resulted in a 38% 
RR reduction (95% CI –58 to –8, p = 0.017) of ﬁ  rst major 
cardiovascular event in older patients similar to the 37% 
reduction (95% CI –57 to –7, p = 0.019) seen in younger 
patients (Neil et al 2006). There was, however, a greater 
reduction in the absolute risk of cardiovascular events in 
older patients (3.9 vs 2.7%) reﬂ  ecting their higher absolute 
risk, and the NNT to avoid one event over 4 years was lower 
in the older group (21 vs 33, respectively).
The Anglo-Scandinavian Cardiac Outcomes Trial-Lipid 
Lowering Arm (ASCOT-LLA) was also designed to study 
lipid lowering in the primary prevention of CHD, in hyper-
tensive patients who were not conventionally deemed dyslip-
idemic (Sever et al 2003). In this study, 10,305 hypertensive 
patients (6570 patients  60 years) without established CHD 
with nonfasting total cholesterol concentrations  251 mg/dL 
and  3 cardiovascular risk factors were randomly assigned 
to receive atorvastatin 10 mg or placebo in addition to 
matched antihypertensive treatment. Follow-up was planned 
for 5 years; however this trial was also stopped prematurely 
after a median of 3.3 years because of signiﬁ  cant reduction 
in the primary endpoint of nonfatal MI and fatal CHD in the 
atorvastatin group compared with placebo (HR 0.64, 95% 
CI 0.50–0.83, p = 0.0005). This impact of atorvastatin on 
the primary endpoint was similar in the older subgroup of 
patients (HR 0.64, 95% CI 0.47–0.86, p = 0.0027). Total car-
diovascular events (HR 0.79, 95% CI 0.69–0.90, p = 0.0005) 
and total coronary events (HR 0.71, 95% CI 0.59–0.86, Clinical Interventions in Aging 2008:3(2) 305
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p = 0.0005) were also signiﬁ  cantly lowered. A 27% reduction 
was seen in incidence of fatal and non-fatal stroke in 
atorvastatin-treated patients (HR 0.73, 95% CI 0.56–0.96, 
p = 0.024). Stroke prevention was similar for patients  70 
years and  70 years (31% vs 24% reduction). As in CARDS, 
to prevent the primary endpoint, a lower number of elderly 
patients needed to be treated in comparison to younger 
patients (83 vs 125, respectively).
Other trials and meta-analyses
Table 3 shows data from other major trials that used a statin 
other than atorvastatin and included elderly participants. 
The Prospective Study of Pravastatin in the Elderly at Risk 
(PROSPER) deserves special mention, as it was the ﬁ  rst 
study of lipid-lowering medication speciﬁ  cally among elderly 
patients. 5804 men and women aged 70–82 years with a his-
tory of or risk factors for vascular disease were randomized 
to pravastatin 40 mg/day or placebo (Shepherd et al 2002). 
During a mean follow-up of only 3.2 years, pravastatin treat-
ment was associated with a signiﬁ  cantly reduced risk of the 
primary end point (composite of coronary death, nonfatal MI 
and fatal or nonfatal stroke) compared to placebo (HR 0.85, 
95% CI 0.74–0.97, p = 0.014). Stroke risk was unaffected 
by therapy, but pravastatin was associated with a lower rate 
of transient ischemic attacks (HR 0.75, 95 CI 0.55–1.00, 
p = 0.051) and signiﬁ  cantly reduced risk of coronary death 
and nonfatal MI (HR 0.81, 95% CI 0.69–0.94, p = 0.006).
The Scandinavian Simvastatin Survival Study (4S) 
included 1021 patients  65 years of age with established 
CHD and hypercholesterolemia (213 to 309 mg/dL) 
(Miettinen et al 1997). Similar reductions in serum lipids 
were observed among elderly and younger individuals with 
simvastatin (20–40 mg/d). Among the elderly, treatment 
with simvastatin was associated with reductions in all-cause 
mortality (HR 0.66, 95% CI 0.48–0.90, p = 0.009), CHD 
mortality (HR 0.57, 95% CI 0.39–0.83, p = 0.003), major 
coronary events (HR 0.66, 95% CI 0.52–0.84, p   0.001) 
and nonfatal MI (HR 0.67, 95% CI 0.51–0.88, p = 0.004). 
For each of these, the NNT was lower in elderly patients 
(see Table 3). More than twice the number of deaths could 
be prevented by simvastatin therapy among the elderly com-
pared with the younger subgroup (61.5 vs 25.5 [all-cause] 
and 60.2 vs 28.1 [CHD] per 1000 patients).
The Cholesterol and Recurrent Events (CARE) trial 
evaluated the effect of pravastatin (40 mg/day) on 1283 
patients aged 65–75 years who had a history of MI and had 
total cholesterol levels in the average range ( 240 mg/dL) 
(Lewis et al 1998). Major coronary events, coronary deaths 
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Atorvastatin in the elderly
and strokes were all signiﬁ  cantly reduced by 32% (95% 
CI 15%–46%, p = 0.001), 45% (95% CI 18%–63%, 
p = 0.004), and 40% (95% CI 4%–62%, p = 0.03), respec-
tively. Compared to younger patients, a lower number of 
elderly people needed statin therapy to avoid these cardio-
vascular outcomes (see Table 3).
The Long-Term Intervention with Pravastatin in Isch-
aemic Disease (LIPID) trial included 3514 patients aged 65 
and 75 years who had a prior infarction or unstable angina in 
addition to average or moderately elevated cholesterol levels 
(155–271 mg/dL) (Hunt et al 2001). Pravastatin (40 mg/day) 
led to reductions in all-cause mortality (HR 0.79, 95% CI 
0.68–0.93, p = 0.003), CHD mortality (HR 0.76, 95% CI 
0.62–0.93, p = 0.009), MI (HR 0.74, 95% CI 0.60–0.91, 
p = 0.005) and stroke (HR 0.88, 95% CI 0.68–1.15, p   0.2) 
in the group  65 years of age. Although the relative effect of 
pravastatin therapy was similar in older and younger patients, 
the absolute risk reduction was greater and the NNT was 
lower in the elderly (see Table 3).
The Heart Protection Study is the largest statin study to be 
done till date. It recruited 20,536 high-risk individuals (5806 
patients  70 years) with cardiovascular disease, diabetes or 
treated hypertension and evaluated the effects of simvastatin 
40 mg/day (HPSCG 2002). There was a 24% reduction (95% 
CI 19%–28%, p   0.0001) in ﬁ  rst major vascular events 
along with signiﬁ  cant reductions in all-cause mortality and 
CHD mortality. The proportional reduction in event rate 
was consistent irrespective of the age of the participants. 
Even among the 1263 individuals 75–80 years of age, major 
vascular events were signiﬁ  cantly reduced with simvastatin 
compared to placebo (23.1% vs 32.3%, p = 0.0002).
A prospective meta-analysis of data from 90,056 individ-
uals in 14 randomized trials of statins was done by the Cho-
lesterol Treatment Trialists’ (CTT) Collaborators (Baigent 
et al 2005). The statin group included 45,054 cardiovascular 
events, of which 16.6% were in subjects aged  65 years. The 
placebo group included 45,002 events of which 20.3% were 
in this age group. Subgroup analysis in patients aged  65 
years revealed a 19% reduction in major coronary events (RR 
0.81, 95% CI 0.76–0.88, p = 0.01) and major vascular events 
(RR 0.81, 95% CI 0.77–0.86, p = 0.1). For those aged  75 
years, an 18% reduction was seen in major coronary events 
(RR 0.82, 99% CI 0.70–0.96, p = 0.002) and major vascular 
events (RR 0.82, 99% CI 0.72–0.93, p   0.001). Another 
meta-analysis evaluated data on 51,351 patients from 18 
randomized, placebo-controlled statin trials to determine 
efﬁ  cacy of statin monotherapy in patients  60 years of age 
(Roberts et al 2007). The statin group showed a signiﬁ  cant 
15% reduction in all-cause mortality (RR 0.85, 95% CI 
0.78–0.93, p = 0.001), 23% reduction in CHD deaths (RR 
0.77, 95% CI 0.71–0.85, p   0.001), 26% reduction in fatal 
or nonfatal MI (RR 0.74, 95% CI 0.70–0.78, p   0.001) and 
24% reduction in fatal or nonfatal stroke (RR 0.76, 95% CI 
0.65–0.90, p = 0.001).
Safety and tolerability
Liver function and creatine kinase (CK)
Statins are generally well tolerated and adverse events are 
usually mild and transient, even among elderly patients. 
In their meta-analysis among patients  60 years of age, 
Roberts et al found musculoskeletal symptoms along with 
abnormalities in CK and liver enzymes to be the most 
commonly reported adverse events (Roberts et al 2007). 
Rates of transaminase elevations  3 times the upper limit 
of normal (ULN) or CK elevations  10 times ULN were 
similar in the statin and placebo groups as were the rates 
of withdrawal from study due to adverse events. In another 
meta-analysis of 23 randomized statin treatment arms with 
309,506 person-years of follow-up, rates of elevated liver 
enzymes increased signiﬁ  cantly with increased statin doses 
for any 10% LDL-C reduction (Alsheikh-Ali et al 2007). 
The rate of liver enzyme elevation with atorvastatin 80 mg/d 
was 4 times greater compared with atorvastatin 10 mg/d 
(p   0.001). Thus, hepatotoxic effects were related to the 
drug and dose used, rather than the magnitude of LDL-C 
lowering. Table 4 summarizes the effects of statins on liver 
enzymes, CK rise as well as rates of rhabdomyolysis from 
major clinical trials.
PROSPER (Shepherd et al 2002) and SAGE (Deedwania 
et al 2007), the only 2 trials which focused exclusively on the 
elderly, had follow-ups of 3.2 years and 1 year, respectively. 
Serious adverse events were similar in the two treatment arms 
in both trials except that liver function test abnormalities were 
more frequent in the atorvastatin group than in the pravastatin 
group (4.3 versus 0.2 %, p   0.001) in SAGE. However, 
liver enzyme levels returned to normal for all patients on 
repeat testing during follow-up or on discontinuation of 
study medication. There were no cases of rhabdomyolysis 
in either study.
Data from other large-scale trials using atorvastatin fur-
ther support these ﬁ  ndings. In the ASCOT (Sever et al 2003) 
and CARDS trials (Colhoun et al 2004) where follow-up was 
relatively short (median 3.3 and 3.9 years, respectively), there 
were no signiﬁ  cant differences in the incidence of serious 
adverse events and liver enzyme abnormalities between the 
atorvastatin (10 mg/day)- and placebo-treated groups. One Clinical Interventions in Aging 2008:3(2) 308
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Atorvastatin in the elderly
case of rhabdomyolysis was reported in a man with very 
high alcohol intake and a recent febrile illness in ASCOT; 
no cases occurred in CARDS. Post hoc analysis of the 
CARDS trial concluded that atorvastatin was equally safe 
and well tolerated among patients aged 65–75 years (Neil 
et al 2006). In PROVE IT, with 2 years follow-up, there was 
no difference between elderly and younger patients in the 
incidence of elevated liver enzymes (2.3 vs. 2.2%, p = 0.8) 
as well as the rates of CK rise (1.1 vs. 1.3%, p = 0.6) (Ray 
et al 2006). Compared with younger patients, the elderly 
did not have any increased rates of discontinuation of study 
drug for myalgia or CK rise or for any other side effect. As 
with younger patients, transient elevations in liver enzymes 
were more likely with atorvastatin (80 mg/d) compared 
with pravastatin (40 mg/d) among the elderly (4.8 vs 0 %, 
p   0.0001). Similar rates of CK rise were seen with both 
regimens in older subjects (1.1%, p = 0.9). There were no 
cases of rhabdomyolysis.
In contrast, in studies with longer follow-up of approxi-
mately 5 years, differences did occur. In IDEAL, high-dose 
atorvastatin (80 mg/day) was associated with increased 
transaminase elevations (0.97% vs 0.11%, p   0.001), 
myalgias (2.2% vs 1.1%, p   0.001) and more nonserious 
adverse events resulting in drug discontinuation (9.6% vs 
4.2%, p   0.001) compared to simvastatin (40 mg/day) 
after 4.8 years of follow-up (Pedersen et al 2005). The 
authors acknowledged the possibility of reporting bias given 
the open-label design of this trial. There were 2 (0.05%) 
cases of rhabdomyolysis with atorvastatin and 3 (0.07%) 
with simvastatin. In TNT, during a median follow-up of 
4.9 years, a greater number of patients receiving high-dose 
atorvastatin had persistent transaminase elevations (1.2% 
vs 0.2%, p   0.001) (LaRosa et al 2005). There were no 
subjects with persistent CK elevation. Five cases of rhabdo-
myolysis were reported in the entire study cohort. All had 
potential confounding factors and were not believed to be 
related to the study drug. Rates of persistent liver enzyme 
elevations with atorvastatin 80 mg/day compared to atorv-
astatin 10 mg/d were 1.3% vs 0.3% for patients  65 years 
and 1.3 vs 0.1% for subjects  65 years of age (Wenger et al 
2007). The differences in adverse event proﬁ  les between 
the treatment groups among the elderly were similar to the 
entire study sample.
Cognitive function
Effect on cognitive function is an area of special concern 
with regard to statin use in the elderly. Statins have been 
shown to cause minor decrements in cognitive function in 
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small studies, manifested as a lack of improvement between 
baseline and post-treatment assessments rather than an abso-
lute decline in performance (Muldoon et al 2000; Muldoon 
et al 2004). In the much larger HPS (HPSCG 2002) and 
PROSPER (Shepherd et al 2002) trials, statins did not have 
any deleterious effects on cognition.
Cancer
In PROSPER, new cancer diagnoses were more frequent in 
patients receiving pravastatin than those receiving placebo 
(Shepherd et al 2002). In one recent meta-analysis, cancer 
rates were signiﬁ  cantly greater in the statin group (RR 1.16, 
95% CI 1.01–1.22, p = 0.04, p for heterogeneity = 0.25) 
in subjects aged 65 years and older (Roberts et al 2007). 
However, this was based on data from 3 trials only and the 
authors acknowledged the need for more consistent report-
ing of cancer rates and longer follow-up periods to further 
study the role of statins among the elderly in this regard. In 
their larger meta-analysis, Alsheikh-Ali et al demonstrated a 
signiﬁ  cant inverse relationship between rates of newly diag-
nosed cancer and achieved LDL-C levels (Alsheikh-Ali et al 
2007). Several meta-analyses of other statin trials, including 
one by the PROSPER authors, have shown no increase in 
cancer risk (Baigent et al 2005; Dale et al 2006).
It is important to note that safety data in clinical trials 
are obtained from a carefully selected and closely monitored 
study population. Subjects with signs of statin intolerance 
(eg, muscular complaints, liver dysfunction) either in the 
past or during the initial run-in phase are usually excluded 
from these studies, as are patients with similar problems at 
baseline. Patients in clinical practice generally have more 
coexisting conditions than study patients, and are usually 
on several concomitant medications which may affect ator-
vastatin metabolism. Also, the limits of acceptable CK and 
transaminase elevations in these studies are certainly higher 
than most physicians would be comfortable with in routine 
practice. Thus, while lower doses of atorvastatin are gener-
ally safe, it is possible that elderly patients may not tolerate 
the high-dose as well as study subjects.
Adherence
Despite their apparent beneﬁ  ts, adherence to statin therapy 
remains low among older patients (Benner et al 2002; 
Jackevicius et al 2002; Benner et al 2005). A retrospective 
cohort study of 34,501 patients  65 years of age measured 
proportion of days (PDC) covered by statins in each quarter 
during the ﬁ  rst year of therapy and every 6 months thereafter, 
in routine care settings (Benner et al 2002). Compliance with 
statin therapy decreased markedly with time, with the largest 
decline observed within the ﬁ  rst 6 months of treatment after 
which mean PDC fell to 56%. Only 43% of patients were 
adherent (deﬁ  ned as PDC  80%) to statin therapy at the end 
of this period. After 5 years, only 1 in 4 patients were still 
adherent to their medications, a number far less than that 
reported in clinical trials. Patients aged  75 years had 19% 
greater odds of poor persistence. Patients with more severe 
baseline CHD had better adherence. Interestingly, this study 
also found that patients who had an MI while on statins were 
less likely to continue statin use following the event. Other 
studies have shown that elderly patients with recent ACS 
are more adherent than those taking statins for stable CHD 
and primary prevention (Jackevicius et al 2002). It has also 
been suggested that greater reductions in LDL-C during 
the ﬁ  rst three months of statin therapy is associated with 
improved adherence (Benner et al 2005). In many clinical 
trials, patients who seem unwilling to comply with long-term 
study medication during the initial run-in period are typically 
excluded from the study to decrease the drop-out rate and 
improve statistical sensitivity. Therefore, results from these 
trials may be less applicable to the general population because 
only “compliers” are included in the actual trial.
Drug interactions
Elderly patients are frequently treated with multiple medica-
tions and so are at increased risk for complications of drug 
interactions. Since statins are highly selective inhibitors of 
HMG-CoA reductase, drug-drug interactions are mainly 
pharmacokinetic, rather than pharmacodynamic. Atorv-
astatin undergoes microsomal metabolism in the liver by 
the cytochrome P-450 3A4 (CYP3A4) isoenzyme. This 
isoenzyme also metabolizes about 60% of all drugs used 
in clinical practice today, increasing the risk of interactions 
(Zhou et al 2005). Antifungal agents (eg, ketoconazole and 
other azoles), antibiotics (eg, clarithromycin, erythromycin 
and isoniazid), antiretrovirals (eg, ritonavir and delavirdine), 
anticancer drugs (eg, tamoxifen and irinotecan), sex steroids 
and estrogen receptor modulators (eg, gestodene and raloxi-
fene), herbal constituents (eg, bergamottin in grapefruit juice 
and glabridin in licorice) and other cardiovascular medica-
tions (eg, hydralazine, verapamil, and diltiazem) inhibit this 
isoenzyme, increase the plasma levels of statins, and may lead 
to statin-related adverse effects (eg, myotoxicity). A recent 
review based on 152 published reports and notiﬁ  cations to 
the US Food and Drug Administration (FDA) of cases of 
statin related rhabdomyolysis showed that these drugs were 
coadministered in 60% of the cases (Law et al 2006). An Clinical Interventions in Aging 2008:3(2) 311
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estimated 19% of cases occurred in patients taking statins 
with fibrates, principally gemfibrozil. Fibrates are not 
CYP3A4 inhibitors and inﬂ  uence the metabolic clearance 
of statins via inhibitory effects on glucuronidation and/or 
non-CYP3A4-mediated oxidative pathways (Prueksaritanont 
et al 2002). In elderly patients, further caution is warranted 
in view of the age-related decline in hepatic drug metabolism 
by the cytochrome system (Cusack 2004).
Cost effectiveness
Ward et al reviewed 31 randomized statin trials to deter-
mine the costs associated with statin treatment taking into 
account the CHD outcomes (Ward et al 2007). Based on a 
threshold of £20,000 per quality adjusted life year (QALY), 
the authors concluded that statin therapy was cost-effective 
in secondary prevention of CHD in all patients aged 45–85 
years. In primary prevention, cost-effectiveness varied 
according to age and level of risk. At an annual CHD risk 
of 3%, between ages 45 and 85 years cost per QALY ranged 
from £9500 to £36,800 for men and £13,700 to £47,400 
for women. At a lower risk of 0.5%, cost per QALY was 
£105,200 and £110,600 for men and women at 85 years of 
age, respectively. They also noted that the cost-effectiveness 
was signiﬁ  cantly enhanced if stroke and transient ischemic 
attack (TIA) outcomes were taken into account, particularly 
among the elderly where the beneﬁ  ts of avoided stroke and 
TIA events are greater. Atorvastatin has been shown to 
be more cost effective compared to ﬂ  uvastatin, lovastatin, 
pravastatin, and simvastatin in various analyses (Huse et al 
1998; Elliott et al 1999). Rosuvastatin is a recently introduced 
potent statin that was found to be more cost-effective than 
atorvastatin based on cost per 1% reduction in LDL-C and 
cost per patient treated to their LDL-C goal in the Statin 
Therapies for Elevated Lipid Levels Compared Across 
Doses to Rosuvastatin (STELLAR) trial (Miller et al 2005). 
However, currently there is no direct trial evidence examin-
ing the effect of rosuvastatin on clinical endpoints of CHD, 
whereas atorvastatin has been widely tested in this regard. 
Also, there is limited evidence on the long-term safety of 
rosuvastatin in large randomized trials.
Alternate-day dosing
Given the prolonged duration of HMG-CoA reductase 
inhibition achieved with atorvastatin, many trials have been 
conducted to evaluate the efﬁ  cacy of alternate-day dosing 
of this drug compared with the standard once-daily dosing. 
The Alternate Day Versus Daily Dosing of Atorvastatin 
Study (ADDAS) randomized 35 hypercholesterolemic 
patients to receive atorvastatin 10 mg as initial dose every 
day or every other day (Matalka et al 2002). The dose was 
doubled if LDL-C goal was not reached at 6 and 12 weeks. 
At 12 weeks, LDL-C reduction was similar in both groups 
(35% in the every-other-day group vs 38% in the every-day 
group, p = 0.49), though the every-day group had greater 
LDL-C reductions at 6 weeks (27% vs 38%, p = 0.01). The 
mean dose was 18 mg (9 mg/day) and 12 mg/day in the 
alternate-day and once-daily groups, respectively (p = 0.001). 
The authors performed a monthly cost analysis based on the 
second phase of the study to calculate the cost of 1% LDL-C 
reduction per patient ($1.22 vs $1.71 in the alternate-day and 
every-day groups, respectively). Using the average wholesale 
price, they calculated a 34% saving in annual drug cost per 
patient for the alternate-day group ($513 vs $782). Another 
similar trial among 54 patients found no statistically sig-
niﬁ  cant differences between atorvastatin 10 mg every day, 
10 mg every other day, and 20 mg every other day for total, 
or a percentage, decrease in total cholesterol and LDL-C at 
6 weeks compared to baseline (Jafari et al 2003). Several 
other studies have concluded that alternate-day dosing of 
atorvastatin is a safe, efﬁ  cacious, and cost-effective alterna-
tive to daily dosing (Piamsomboon et al 2002; Juszczyk et al 
2005; Ferrer-García et al 2006).
Management strategies and place 
in therapy
Table 5 highlights some of the key points discussed in this 
paper. Elderly patients are at high risk of heart disease and 
statin therapy has been proven to have a favorable effect on 
the cardiovascular outcome in these patients. In 2001, the 
Table 5 Key messages from this review
•   Elderly individuals are more likely to have heart disease, particularly 
subclinical atherosclerosis.
•   Atorvastatin is the most potent statin with proven beneﬁ  t in terms of 
improved clinical outcomes.
•   Atorvastatin has been widely tested among older people, both with 
and without known coronary heart disease.
•   Elderly patients beneﬁ  t equally, if not more, with atorvastatin therapy 
compared to their younger counterparts.
•   Atorvastatin therapy in these patients is cost-effective when con-
sidering cardiovascular outcomes and cost-savings from reduced 
hospitalization.
•   Lower doses of statins are generally safe in the elderly population.
•   Atorvastatin is also effective in an alternate dose regimen, which 
makes it particularly attractive for older patients having statin-related 
adverse effects.
•   Therefore, the risk-beneﬁ  t ratio for atorvastatin therapy remains 
favorable even in older individuals.Clinical Interventions in Aging 2008:3(2) 312
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Third report of the National Cholesterol Education Program 
(NCEP) Adult Treatment Panel recommended that persons 
older than 65 years of age should not be denied the beneﬁ  ts 
of LDL-lowering therapy (NCEP 2001). Based on data from 
HPS and PROSPER, these recommendations were updated 
in 2004 (Grundy et al 2004). The NCEP concluded that 
strong justiﬁ  cation existed for LDL-lowering therapy in older 
persons with established CVD. For elderly patients without 
established CVD, the NCEP relied on additional data from 
PROSPER and ASCOT to recommend the use of clinical 
judgment in addition to the Framingham risk score for initiat-
ing lipid-lowering therapy. Such patients may have subclini-
cal atherosclerosis which would make lipid lowering with 
statins beneﬁ  cial. New data from the SAGE and PROVE-IT 
subanalysis support the use of aggressive lipid modiﬁ  cation 
(LDL-C goal  70 mg/dL) in elderly patients at particularly 
high-risk, especially those with recent coronary events.
Atorvastatin is one of the more potent statins in terms of 
LDL-C lowering and has been shown to have several ben-
eﬁ  cial pleiotropic effects on underlying atherosclerosis over 
and above lipid lowering. It has been widely tested among 
the elderly in clinical trials as well as in real-life patients in 
clinical practice. The SAGE trial included patients as old as 
85 years of age, suggesting that the beneﬁ  ts of atorvastatin 
can extend up to that age. Of all the statins proven to improve 
CHD outcomes, atorvastatin is the most cost-effective. 
Therapy in older CHD patients may be more cost-effective 
compared with their younger counterparts despite their 
shorter life expectancy. This is because higher baseline risk in 
older individuals allows greater cost savings from decreased 
rates of hospitalization resulting from preventive treatment 
(Tonkin et al 2006). The pharmacokinetic properties of ator-
vastatin make it suitable for every-other-day dosing, which 
can further enhance its cost-effectiveness.
Special efforts should be made to increase compliance to 
statin therapy among elderly patients, particularly in those 
with stable disease. Older patients may be more susceptible 
to adverse effects of these drugs. A careful medical history 
should be elicited prior to initiating statin therapy, with 
special emphasis on concomitant medications and medi-
cal illnesses which may make patients unsuitable for such 
therapy. Careful monitoring is required, even though most 
of the adverse effects are relatively minor and reversible. In 
clinical practice, many elderly patients may still be unable 
to reach their lipid goals due to statin-related symptoms or 
laboratory abnormalities. Such patients should be switched to 
an alternate-day regimen of atorvastatin since statin-related 
adverse effects may not be as prominent on an every-other-day 
dosing, thus, allowing these patients to achieve their LDL-C 
goals.
In conclusion, beneﬁ  ts of statin therapy far outweigh any 
safety concerns, especially among older CHD patients who 
may be otherwise healthy. By reducing morbidity related to 
acute coronary events, statins can enhance the quality of life 
and lead to a more productive old age. While extra caution is 
warranted with high-dose statin therapy, particularly in those 
with concomitant medical conditions such as chronic kidney 
or liver disease, increased chronological age alone should 
not exclude any patient from receiving the beneﬁ  ts of such 
treatment. Atorvastatin has been proven to improve clinical 
outcomes, even when compared to other statins in large 
randomized clinical trials, and is generally well tolerated in 
the elderly population. It is therefore a suitable choice when 
considering statin therapy in this group of patients.
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